CCI
FOLD

Columbus Circle Investors’s Amicus Therapeutics FOLD Stock Holding History

Columbus Circle Investors’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-59,900
Closed -$506K – 269
2016
Q1 		$506K Buy
+59,900
New +$424K ﹤0.01% 252

Other funds holding FOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Columbus Circle Investors's FOLD Position: Q4 2017 in Review

Columbus Circle Investors sold out of Amicus Therapeutics (FOLD) in Q4 2017, closing a stake of 199,874 shares — an estimated $3.01M sold.

Columbus Circle Investors first reported a position in FOLD in Q3 2014 and held it in 13 quarters. The position peaked at $3.01M in Q3 2017. 185 funds tracked by Wall St. Rank hold FOLD as of Q4 2017.

  • Columbus Circle Investors reported no remaining Amicus Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Columbus Circle Investors sold 199,874 Amicus Therapeutics shares in Q4 2017, an estimated $3.01M.
  • Columbus Circle Investors first reported a position in Amicus Therapeutics in Q3 2014 and held it in 13 quarters.
  • Columbus Circle Investors's Amicus Therapeutics position peaked at $3.01M in Q3 2017.
  • 185 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2017.

Based on Columbus Circle Investors's 13F filing for Q4 2017, filed 2 Feb 2018.